

Product specifications

Name	Anti-h PSA 8301 SPRN-5
Specificity	Antibody recognizes human prostate-specific antigen
Description	Monoclonal mouse antibody, cultured <i>in vitro</i> under conditions free from animal-derived components
Product code	100102
Product buffer solution	37 mM citrate, 125 mM phosphate, pH 6.0, 0.9 % NaCl, 0.095 % NaN ₃ as a preservative
Shelf life and storage	36 months from manufacturing at 2–8 °C
Subclass	IgG ₁
Analyte description	Prostate-specific antigen (PSA) is a protein produced by the cells of the prostate gland. PSA is present in small quantities in the serum of healthy men, and is often elevated in the presence of prostate cancer and in other prostate disorders. A blood test to measure PSA is considered the most effective test currently available for the early detection of prostate cancer, but this effectiveness has also been questioned.

Parameters tested on each lot

Product appearance	Liquid, may turn slightly opaque during storage
Product concentration	5.0 mg/ml (+/- 10 %)
Immunoreactivity	80–120 % compared to the reference sample in an FIA test
IEF Profile	6.5–7.2
Purity	≥ 95 %

Kinetic parameters

Association rate constant	Not Determined (N/D)
Dissociation rate constant	N/D
Affinity constant	1 x 10 ¹¹ 1/M
Determination method	Radioimmunoassay (RIA)
Determination antigen	PSA, Aalto (Cat AJ 3036, Lot 1133)

Legal disclaimer



Cross-reactivities

PSA/ α 1-ACT complex	59 % (Scripps Laboratories, Cat P0624, Lot 777464)
Kallikrein	< 0.04 % (Biosdesign, Cat P0514, Lot 191K)
PAP	< 0.04 % (Scripps Laboratories, Cat P0514, Lot 534164 A)

Epitope Residues 158–163, group 3 as described in Rye et al. (1999)

Pair recommendations

		DETECTION			
		8301	8311	8312	8313 (free PSA)
CAPTURE	8301	-	+	+	+
	8311	+	-	-	+
	8312	+	-	-	+
	8313 (free PSA)	+	+	+	-

Please note that pair recommendations are based on results obtained by our laboratory. Equally good results may be obtained using other pairs and therefore these recommendations are only indicative..

Platforms tested FIA

Antigens tested Native PSA antigen, Lee Biosolutions 497-11 and 497-17, and native PSA-ACT complex, Lee Biosolutions 498-11.

TEMPERATURE, TIME	RESULT
-70 °C, 21 days	N/D
-20 °C, 21 days	OK
+4 °C, 21 days	OK
+30 °C, 21 days	OK
+35 °C, 21 days	OK
+45 °C, 7 days	OK

Stability testing is performed in the product buffer to see whether different temperatures affect the antigen binding, charge or composition of the antibody. Please note that the shelf life given on the first page is based on real time stability testing at 2–8 °C in the product buffer.

Miscellaneous Clone 8301 reacts with non-reduced and reduced intact PSA but not with reduced PSA fragments (Rye et al., 1999). In the same study affinities for free-PSA and PSA-ACT-complex were, 9.0×10^{-9} mol/l and 5.2×10^{-9} , respectively. They also noted that antibodies binding to epitope group 3a form a good pair with antibodies from groups 1, 5a, 5c and 6. Clone 8301 does not cross-react with human kallikrein-2 (Black, 1999b).

References Black, M.H., Grass, C.L., Leinonen, J., Stenman, U-H. and Diamandis, E.P., (1999a) Characterization of monoclonal antibodies for prostate-specific antigen and development of highly sensitive free prostate-specific antigen assays. Clin. Chem., 45(3):347-354

Black, M.H., Magklara, A., Obiezu, C.V., Melegos, D.N. and Diamandis, E.P., (1999b) Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. Clin. Chem., 45(6):790-799

Ferguson, R.A., Yu, H., Kalyvas, M., Zammit, S. and Diamandis, E.P., (1996) Ultrasensitive detection of prostate-specific antigen by time-resolved immunofluorometric assay and the

Immulite® immunochemiluminescent third-generation assay: potential applications in prostate and breast cancer. *Clin. Chem.*, 42(5):675-684

Magklara, A., Scorilas, A., López-Otín, C., Vizoso, F., Ruibal, A. and Diamandis, E.P., (1999) Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid. *Clin. Chem.*, 45(10):1774-1780

Obiezu, C.V., Giltay, E.J., Magklara, A., Scorilas, A., Gooren, L.J.G., Yu, H., Howarth, D.J.C. and Diamandis, E.P., (2000) Serum and urinary prostate-specific antigen and urinary human glandular kallikrein concentrations are significantly increased after testosterone administration in female-to-male transsexuals. *Clin. Chem.*, 46(6):859-862

Rye, P.D., Bormer, O.P. and Paus, E. (guest editors) (1999), ISOBM TD-3 International Workshop on monoclonal antibodies against prostate-specific antigen. *Tumor Biol.*, 20(suppl 1):1-94

